WO2000007624A3 - Pharmaceutical composition having inhibitory effect on overproduction and accumulation of extracellular matrix - Google Patents

Pharmaceutical composition having inhibitory effect on overproduction and accumulation of extracellular matrix Download PDF

Info

Publication number
WO2000007624A3
WO2000007624A3 PCT/JP1999/004238 JP9904238W WO0007624A3 WO 2000007624 A3 WO2000007624 A3 WO 2000007624A3 JP 9904238 W JP9904238 W JP 9904238W WO 0007624 A3 WO0007624 A3 WO 0007624A3
Authority
WO
WIPO (PCT)
Prior art keywords
overproduction
accumulation
pharmaceutical composition
extracellular matrix
inhibitory effect
Prior art date
Application number
PCT/JP1999/004238
Other languages
French (fr)
Other versions
WO2000007624A2 (en
Inventor
Satoshi Sasaki
Yoshihiko Sumi
Reginald Colin Hughes
Original Assignee
Teijin Ltd
Satoshi Sasaki
Yoshihiko Sumi
Reginald Colin Hughes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Ltd, Satoshi Sasaki, Yoshihiko Sumi, Reginald Colin Hughes filed Critical Teijin Ltd
Priority to JP2000563306A priority Critical patent/JP2002522398A/en
Priority to EP99935073A priority patent/EP1104307B1/en
Priority to AU50653/99A priority patent/AU5065399A/en
Priority to DE69931791T priority patent/DE69931791T2/en
Publication of WO2000007624A2 publication Critical patent/WO2000007624A2/en
Publication of WO2000007624A3 publication Critical patent/WO2000007624A3/en
Priority to HK01108540A priority patent/HK1038308A1/en
Priority to US12/123,265 priority patent/US20080219973A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/739—Lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A pharmaceutical composition having an inhibitory effect on the overproduction and the accumulation of extracellular matrix, said composition comprising as an active ingredient a compound that inhibits the biological activity of galectin-3, which pharmaceutical composition can serve as a therapeutic or preventive agent for glomerular nephritis, diabetic nephropathy or tissu fibrosis, as well as the use of said compound for the production of pharmaceuticals for the above-mentioned use, and a method for inhibition of the overproduction and accumulation of the extracellular matrix.
PCT/JP1999/004238 1998-08-06 1999-08-05 Pharmaceutical composition having inhibitory effect on overproduction and accumulation of extracellular matrix WO2000007624A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2000563306A JP2002522398A (en) 1998-08-06 1999-08-05 Pharmaceutical compositions showing efficacy against overproduction and accumulation of extracellular matrix
EP99935073A EP1104307B1 (en) 1998-08-06 1999-08-05 Pharmaceutical composition having inhibitory effect on overproduction and accumulation of extracellular matrix
AU50653/99A AU5065399A (en) 1998-08-06 1999-08-05 Pharmaceutical composition having inhibitory effect on overproduction and accumulation of extracellular matrix
DE69931791T DE69931791T2 (en) 1998-08-06 1999-08-05 PHARMACEUTICAL COMPOSITION THAT HAS AN INHIBITANT EFFECT ON THE OVERPRODUCTION AND ACCUMULATION OF THE EXTRACELLULAR MATRIX
HK01108540A HK1038308A1 (en) 1998-08-06 2001-12-05 Pharmaceutical composition having inhibitory effect on overproduction and accumulation of extracellular matrix
US12/123,265 US20080219973A1 (en) 1998-08-06 2008-05-19 Pharmaceutical Composition Having Inhibitory Effect on Overproduction and Accumulation of Extracellular Matrix

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP23349998 1998-08-06
JP10/233499 1998-08-06

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/928,407 Continuation US20050032675A1 (en) 1998-08-06 2004-08-30 Pharmaceutical composition having inhibitory effect on overproduction and accumulation of extracellular matrix

Publications (2)

Publication Number Publication Date
WO2000007624A2 WO2000007624A2 (en) 2000-02-17
WO2000007624A3 true WO2000007624A3 (en) 2000-06-22

Family

ID=16955990

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1999/004238 WO2000007624A2 (en) 1998-08-06 1999-08-05 Pharmaceutical composition having inhibitory effect on overproduction and accumulation of extracellular matrix

Country Status (6)

Country Link
EP (1) EP1104307B1 (en)
JP (1) JP2002522398A (en)
AU (1) AU5065399A (en)
DE (1) DE69931791T2 (en)
HK (1) HK1038308A1 (en)
WO (1) WO2000007624A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0100172D0 (en) * 2001-01-22 2001-01-22 Ulf Nilsson New inhibitors against galectins
JP2002322082A (en) * 2001-04-26 2002-11-08 Purotejiin:Kk Prophylactic and therapeutic agent for nephritis
EP1980257A1 (en) * 2003-04-07 2008-10-15 Prospect Therapeutics, Inc. Compositions and uses of galectin antagonists
US20050053664A1 (en) 2003-09-08 2005-03-10 Eliezer Zomer Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
US8128966B2 (en) 2004-03-26 2012-03-06 La Jolla Pharmaceutical Company Modified pectins, compositions and methods related thereto
JP2005314252A (en) * 2004-04-27 2005-11-10 Okayama Univ Prophylactic/therapeutic agent for diabetic nephropathy
SE0401300D0 (en) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel Galactoside Inhibitors of Galectins
SE0401301D0 (en) * 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel 3-triazolyl-galactoside inhibitors or galectins
AU2015229658A1 (en) * 2014-03-10 2016-09-29 La Jolla Pharmaceutical Company Compositions and methods for treating kidney disorders
CA3127113A1 (en) 2019-01-30 2020-08-06 Dongxu Sun Anti-gal3 antibodies and uses thereof
EP4125937A4 (en) * 2020-03-23 2024-05-22 G3P, Inc. Methods and compositions for preventing and treating fibrosis resulting from a coronavirus infection

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HENRICK K ET AL: "Evidence for subsites in the galectins involved in sugar binding at the nonreducing end of the central galactose of oligosaccharide ligands: sequence analysis, homology modeling and mutagenesis studies of hamster galectin-3.", GLYCOBIOLOGY, (1998 JAN) 8 (1) 45-57., XP000876954 *
LIU F T ET AL: "Modulation of functional properties of galectin -3 by monoclonal antibodies binding to the non-lectin domains.", BIOCHEMISTRY, (1996 MAY 14) 35 (19) 6073-9., XP002131317 *
OCHIENG J ET AL: "Regulation of cellular adhesion to extracellular matrix proteins by galectin-3.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, (1998 MAY 29) 246 (3) 788-91., XP002131316 *
PROBSTMEIER R ET AL: "Galectin-3, a beta-galactoside-binding animal lectin, binds to neural recognition molecules.", JOURNAL OF NEUROCHEMISTRY, (1995 JUN) 64 (6) 2465-72., XP000876914 *

Also Published As

Publication number Publication date
DE69931791T2 (en) 2007-05-24
AU5065399A (en) 2000-02-28
DE69931791D1 (en) 2006-07-20
EP1104307A2 (en) 2001-06-06
EP1104307B1 (en) 2006-06-07
JP2002522398A (en) 2002-07-23
WO2000007624A2 (en) 2000-02-17
HK1038308A1 (en) 2002-03-15

Similar Documents

Publication Publication Date Title
WO2004050040A3 (en) Pharmaceutical composition of 1-(3,4-dimethoxyphenyl)-4-methyl-5-ethyl-7-methoxy-8-hydroxy-5h-2,3-benzodiazepine and uses thereof
CA2386690A1 (en) Pharmaceutical tramadol salts
WO2000007624A3 (en) Pharmaceutical composition having inhibitory effect on overproduction and accumulation of extracellular matrix
NO20031024D0 (en) Bicyclic pyrrolyl amides as glucogenic phosphorylase inhibitors
WO2003024955A3 (en) Small molecule inhibitors of caspases
WO2004050034A3 (en) Prolonged suppression of electrical activity in excitable tissues
WO2000003997A1 (en) Thiobenzimidazole derivatives
IL165383A (en) Pharmaceutical compositions comprising a salt or co-crystal of celecoxib, surfactant and a cellulose derivative
BR0012046A (en) Heterocyclic compound, pharmaceutical composition, inhibitor of activation of ap-1 or an inhibitor of activation of nf-kappab, inhibitor of the production of inflammatory cytokine, and inhibitor of the production of matrix metalloprotease or inhibitor of the expression of inflammatory cell adhesion factor
MY140999A (en) Dispersible tablets comprising a benzoic acid derivative
HK1080459A1 (en) Novel pyrimidineamide derivatives and the use thereof
WO2010147430A3 (en) Novel c-aryl glucoside sglt2 inhibitors and pharmaceutical composition comprising same
EP1797897A4 (en) Medicinal composition containing meltrin antagonist
HK1070883A1 (en) R-(-)-1-2-(7-chlorobenzo-b-thiophen-3-yl-methoxy)-2(2,4-dichlorophenyl)ethyl-1h-imidazole
CA2337797A1 (en) Naaladase inhibitors useful as pharmaceutical compounds and compositions
MXPA03008420A (en) Solid orally-dispersible pharmaceutical formulation.
EP1602645A4 (en) Nitrogenous heterocyclic derivative having 2,6-disubstituted styryl
TW200637542A (en) Lipase inhibitor, preventing and treating agent of skin disease
WO2000040232A3 (en) Bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
AU1305501A (en) Novel metalloprotease having aggrecanase activity
WO2004056768A3 (en) Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
EP1632241A4 (en) Preventive and/or remedy for diseases accompanied by tissue destruction
CA2320627A1 (en) Medicament for treatment of diastolic dysfunction
EP1550667A4 (en) Tyrosinase activity controlling agents, process for producing the same and external preparations containing the same
WO2004069155A3 (en) Pharmaceutical composition of 1-(3-hydroxy-4-methoxyphenyl)-4-methyl-5-ethyl-7,8-dimethoxy-5h-2,3-benzodiazepine and uses therof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 1999935073

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09744328

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1999935073

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 1999935073

Country of ref document: EP